No Data
TEDA BIOMEDICAL (08189.HK) plans to offer a discount of about 18.46% to place up to 0.239 billion shares, raising a net amount of 63 million Hong Kong dollars.
On January 16, Gelonghui announced that TEDA BIOMEDICAL (08189.HK) entered into a placement agreement with the placement agent on January 16, 2025. According to this agreement, the placement agent conditionally agrees to use its best efforts to procure no fewer than six (6) subscribers (who, along with their ultimate beneficial owners, must be independent third parties) to subscribe for up to 239,400,000 placement shares at a placement price of HKD 0.265 per share. The maximum number of placement shares, 239,400,000 shares, represents approximately 12.64% of the company’s existing issued share capital as of the date of this announcement.
Express News | Tianjin TEDA Biomedical Engineering - to Place 239.4 Mln Placing Shares at HK$0.265 per Share
Citic sec: Global demand remains strong, and the leading potash fertilizer producer's production cut may raise prices.
Citic sec predicts that the supply and demand for global potassium fertilizer will be tight in 2025, and potassium fertilizer prices are expected to rebound from the bottom.
Sinolink: Potash fertilizer supply is expected to be jointly controlled, and resource prices are expected to provide support.
Only 11 companies have a potassium chloride production capacity exceeding 2 million tons, mainly concentrated in Canada nutrien, Belarus Belaruskali, Russia Uralkali, and the usa Mosaic, with a combined production capacity accounting for 67.26% of the industry, high industry concentration.
Teda Biomedical (08189) has appointed Liu Jinyu as the Chairman of the Supervisory Board.
teda biomedical (08189) announced that Ms. Yang Chunyan has resigned from the company and has submitted her resignation to the board of supervisors, resigning as a supervisor and...
Trending Industry Today: LANDSEA MGMT Leads Gains In Retirement Planning Stocks
